Drug intelligence / Profile preview

Ancer

Development stage: Unknown

Overview

**Ancer** is a non-specific trade-name query rather than one uniquely identifiable drug. In Japan, Ancer is the Zeria product containing Z-100, a hot-water extract of *Mycobacterium tuberculosis* strain Aoyama B, marketed for leukopenia associated with radiotherapy and investigated with radiotherapy for cervical cancer. Separately, Indian medicine listings use Ancer for a fixed-dose common-cold tablet containing caffeine, levocetirizine, paracetamol, and phenylephrine. These products have different active substances, mechanisms, dosage forms, developers, and indications, so they must not be merged into one drug record. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9733245/))

Brand names: Ancer

Beyond the preview

Go deeper on Ancer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ancer.

Explore the full profile